

**Enjaymo (sutimlimab-jome)**  
**Effective 9/01/2022**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

Enjaymo is indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).

### Coverage Guidelines

Authorization may be reviewed for members new to the plan who are currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

#### OR

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. Member has a diagnosis of primary cold agglutinin disease (CAD)
2. Prescribed by or in consultation with a hematologist
3. Documented history of at least one blood transfusion in previous six months before the initiation of treatment with Enjaymo

### Continuation of Therapy

Reauthorization requires physician attestation there is no evidence of unacceptable toxicity or disease progression while on the current regimen (e.g., a reduction in blood transfusion)

### Limitations

1. Initial approvals will be granted for 6 months
2. Reauthorizations will be granted for 12 months.

## Review History

07/20/22 – Reviewed and created for July P&T. Effective 9/01/2022

## References

1. Enjaymo [package insert]. Waltham, MA: Bioverativ USA Inc Inc.; February 2022.
  2. Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, et al. Sutimlimab in cold agglutinin disease. *N Engl J Med.* 2021;384(14):1323–34.
- Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. *Blood Rev.* 2020;41:100648.

